Addex to Participate in the H.C. Wainwright 26th Annual Global Investment Conference
September 04 2024 - 12:00AM
Geneva, Switzerland, September 4, 2024
- Addex Therapeutics (SIX/NASDAQ: ADXN), a clinical-stage
biopharmaceutical company focused on developing a portfolio of
novel small molecule allosteric modulators for neurological
disorders, announced today that CEO, Tim Dyer, will be attending
the H.C. Wainwright 26th Annual Global Investment Conference taking
place September 9 – 11, 2024, at the Lotte New York Palace
Hotel.
A pre-recorded video presentation by Mr. Dyer in
which he provides a corporate update and discusses recent
developments at Addex, will be available for viewing on-demand from
07:00 EDT on Monday, September 9, 2024, via the following webcast
link.
Mr. Dyer will be available for one-on-one
meetings throughout the conference. For more information or to
schedule a meeting, please contact IR@addexpharma.com.
About Addex:Addex
Therapeutics is a clinical-stage biopharmaceutical company
focused on developing a portfolio of novel small molecule
allosteric modulators for neurological disorders. Addex lead drug
candidate, dipraglurant (mGlu5 negative allosteric modulator or
NAM), is under evaluation for future development in brain injury
recovery including post-stroke and traumatic brain injury recovery.
Addex partner, Indivior, has selected a GABAB PAM drug candidate
for development in substance use disorders and expects to start IND
enabling studies in H1 2025. Addex is advancing an independent
GABAB PAM program for chronic cough and expect to start IND
enabling studies in 2025. Addex is also holding a 20% equity
interest in a private company, Neurosterix LLC, which is advancing
a portfolio of allosteric modulator programs including M4 PAM for
schizophrenia, mGlu7 NAM for mood disorders and mGlu2 NAM for mild
neurocognitive disorders. Addex shares are listed on the SIX Swiss
Exchange and American Depositary Shares representing its shares are
listed on the NASDAQ Capital Market, and trade under the ticker
symbol “ADXN” on each exchange. For more information,
visit www.addextherapeutics.com
Contacts:
Tim DyerChief
Executive OfficerTelephone: +41 22 884 15
55PR@addextherapeutics.com |
Mike
SinclairPartner, Halsin Partners+44 (0)20 7318
2955msinclair@halsin.com |
Addex Forward Looking
Statements:This press release contains forward-looking
statements within the meaning of the Private Securities Litigation
Reform Act of 1995, as amended, including statements about the
intended use of proceeds of the offering. The words “may,” “will,”
“could,” “would,” “should,” “expect,” “plan,” “anticipate,”
“intend,” “believe,” “estimate,” “predict,” “project,” “potential,”
“continue,” “target” and similar expressions are intended to
identify forward-looking statements, although not all
forward-looking statements contain these identifying words. Any
forward-looking statements in this press release, are based on
management's current expectations and beliefs and are subject to a
number of risks, uncertainties and important factors that may cause
actual events or results to differ materially from those expressed
or implied by any forward-looking statements contained in this
press release, including, without limitation, uncertainties related
to market conditions. These and other risks and uncertainties are
described in greater detail in the section entitled “Risk Factors”
in Addex Therapeutics’ Annual Report on Form 20-F for the year
ended December 31, 2023, as filed with the SEC on April 18, 2024,
the final prospectus supplement and accompanying prospectus and
other filings that Addex Therapeutics may make with the SEC in the
future. Any forward-looking statements contained in this press
release represent Addex Therapeutics’ views only as of the date
hereof and should not be relied upon as representing its views as
of any subsequent date. Addex Therapeutics explicitly disclaims any
obligation to update any forward-looking statements.
Addex Therapeutics (NASDAQ:ADXN)
Historical Stock Chart
From Nov 2024 to Dec 2024
Addex Therapeutics (NASDAQ:ADXN)
Historical Stock Chart
From Dec 2023 to Dec 2024